SCHEMBL12435377

SCHEMBL12435377

CNC(=O)c1ccc(-c2ccc(OC)c(-c3ccc(C)cc3CN3C(=O)O[C@H](c4cc(C)cc(C(F)(F)F)c4)[C@@H]3C)c2)c(C)c1

nearest known ligand 0.74

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CETP P11597 20/20 0.74
KCNH2 Q12809 6/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12434865 0.94 CETP (0.75) CETPKCNH2
SCHEMBL12434929 0.93 CETP (0.85) CETPKCNH2
SCHEMBL12435381 0.93 CETP (0.76) CETPKCNH2
SCHEMBL12512493 0.93 CETP (0.85) CETPKCNH2
SCHEMBL12435236 0.91 CETP (0.73) CETPKCNH2
SCHEMBL12435380 0.90 CETP (0.72) CETPKCNH2
SCHEMBL12435143 0.88 CETP (0.69) CETPKCNH2
SCHEMBL12434938 0.88 CETP (0.83) CETPKCNH2
SCHEMBL12434901 0.88 CETP (0.72) CETPKCNH2
SCHEMBL14942911 0.88 CETP (0.74) CETPKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8440702-B2 1,3-oxazolidin -2-one derivatives useful as CETP inhibitors MERCK SHARP & DOHME CORP. (US) 2013-05-14 US disclosed
US-20110178059-A1 1,3-OXAZOLIDIN -2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178059-A1 1,3-OXAZOLIDIN -2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS CETP, MTTP, APOB CETP 1/4885KCNH2 4335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.